Key clinical point: Individuals undergoing allogeneic blood or marrow transplantation (BMT) in childhood require careful follow-up for many years because of a persistent elevated risk of premature death.
Major finding: Risk of premature death was increased 14.4-fold, compared with the general population (95% confidence interval, 12.8-16.1).
Study details: A retrospective cohort study including 1,388 individuals living 2 years or more after allogeneic BMT performed in childhood.
Disclosures: The study was supported in part by grants from the National Cancer Institute, the Leukemia Lymphoma Society, and the Swedish Childhood Cancer Foundation. Dr. Holmqvist and her coauthors reported no conflicts of interest.
Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.
This Week's Must Reads
Must Reads in Hodgkin Lymphoma
Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.
PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.